2018
Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S, Lafourcade B, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo J, Gessner B, Meda N, Borrow R, Trotter C, Mueller J. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Clinical Infectious Diseases 2018, 68: 435-443. PMID: 30481265, DOI: 10.1093/cid/ciy488.Peer-Reviewed Original ResearchConceptsPre-vaccination levelsAge groupsBooster campaignAntibody persistenceMeningococcal serogroup A conjugate vaccineSerum bactericidal antibody titersBactericidal antibody titersYounger age groupsOlder age groupsImmunoglobulin G concentrationCross-sectional surveyTime of returnDifferent age groupsConjugate vaccineAntibody titersImmune protectionGeneral populationMass vaccinationSerological surveyComplete returnOlder individualsMass campaignsBurkina FasoGeometric meanBobo-Dioulasso
2013
The effects of the acute phase response on biomarkers of iron status differ in the presence of malaria infection
Wessells R, Hess S, Ouedraogo Z, Rouamba N, Erhardt J, Ouedraogo J, Brown K. The effects of the acute phase response on biomarkers of iron status differ in the presence of malaria infection. The FASEB Journal 2013, 27: 107.7-107.7. DOI: 10.1096/fasebj.27.1_supplement.107.7.Peer-Reviewed Original ResearchC-reactive proteinAcute phase responseIron statusAsymptomatic childrenSubclinical inflammationPlasma ferritinMalaria infectionMalarial parasitemiaPhase responseHigh prevalenceHigher geometric meanMalariaPrevalenceAP proteinInflammationChildrenInfectionGrant funding sourcesDeficiencyAGPGeometric meanStatusAntigenemiaBurkina FasoParasitemia